Alpha Thalassemia Major clinical trials at UCSF
2 in progress, 1 open to eligible people
Alpha thalassemia major is a life-threatening blood condition present from fetal development that causes severe anemia. UCSF is maintaining an international patient registry that records clinical and pregnancy information. UCSF is using the registry to document fetal and newborn outcomes over time.
International Registry of Patients With Alpha Thalassemia
open to all eligible people
This is an international prospective registry of patients with Alpha thalassemia to understand the natural history of the disease and the outcomes of fetal therapies, with the overall goal of improving the prenatal management of patients with Alpha thalassemia.
San Francisco, California
EDIT-301 for Autologous Hematopoietic Stem Cell Transplant (HSCT) in Participants With Transfusion-Dependent Beta Thalassemia (TDT)
Sorry, in progress, not accepting new patients
The purpose of this study is to evaluate the safety, tolerability, and efficacy of treatment with EDIT-301 in adult participants with Transfusion Dependent beta Thalassemia
Oakland, California and other locations
Our lead scientists for Alpha Thalassemia Major research studies include Tippi C MacKenzie, MD.
Last updated: